Back to results
US 2006/0216292 A1Published application
Treatment of neurodegenerative diseases
AssigneeCellzome Limited
InventorCarsten Hopf
Life of this patent
Estimating the term…
Abstract
The present invention relates to the uses of FADS2 interacting molecules, especially FADS2 inhibitors, for the preparation of a medicament for the treatment of neurodegenerative diseases, specially Alzheimer's disease.
Claims66
A pharmaceutical composition for the treatment of neurogenerative diseases comprising a FADS2 interacting molecule.
A method for identifying a gamma secretase and/or a beta secretase modulator comprising the following steps:
- a). identifying of a FADS2-interacting molecule by determining whether a given test compound is a FADS2-interacting molecule, and
- b). determining whether the FADS2-interacting molecule of step a) is capable of modulating gamma secretase and/or beta secretase activity.
A protein complex comprising
- a) FADS2 and
- b) either one or more proteins of the Nicastrin (a) complex, of the Nicastrin (b) complex, of the Nicastrin (c) complex, of the BACE1-complex (a), of the BACE1-complex (b), of the Psen2-complex or of the PTK7 complex.
(canceled)
38-40. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.